Research Nester’s recent market research analysis on “Dyspepsia Drugs Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global dyspepsia drugs market in terms of market segmentation by type, end-user, indication, drug type, medication and by region.
Rising Health Awareness Among the Population and Rising Preference for the Counter to Promote Global Market Share of Dyspepsia Drugs Market
The global dyspepsia drugs market is estimated to grow majorly on the back of rising dyspepsia in the population. Moreover, the rising consumption of junk food is also leading to increased problems associated to the acid reflux. For instance, almost 92% of US children and 86.1% of US adults reported at least some junk food consumption in the year 2021. Moreover, functional dyspepsia is considered to be one of the most common disorders and almost 11% to 20% of people who seek healthcare may have functional dyspepsia. Also, almost 6 in 10 people feels recurring bouts of dyspepsia. These factors are anticipated to bolster the growth of the global dyspepsia drugs market during the forecasted period. Furthermore, the diseases are also associated with aging, and their occurrence tends to remain prominent in the older population. Some age-related changes in the digestive system, such as changes in gastric motility and reduced stomach acid secretion. The rising utilization and demand of dyspepsia drugs among the aging population is anticipated to render support the growth of global dyspepsia drugs market.
Some of the major growth factors and challenges that are associated with the growth of the global dyspepsia drugs market are:
Growth Drivers:
• Surging Prevalence of GERD (Gastroesophageal Reflux Disease)
• Rising Awareness and Diagnosis Rates
Challenges:
Surging generic competition, side effects & safety concerns, and increased preference for natural remedies are some of the major factors anticipated to hamper the global market size of global dyspepsia drugs market.
Access our detailed report at: https://www.researchnester.com/reports/dyspepsia-drugs-market/5649
By end-users, the global dyspepsia drugs market is segmented into hospitals, retail pharmacies, and online pharmacies. The hospital segment is anticipated to garner a remarkable share in the year 2036. The increasing problems related to perforated ulcers, gastrointestinal bleeding, and refractory dyspepsia are increasing hospitalization.
By region, the Europe dyspepsia drugs market is to generate the highest revenue by the end of 2036. Europe's dyspepsia drug market is projected to grow at a CAGR of almost 4.71% during the forecast period. The reason for the growth in the forecast period due to rising prevalence of dyspepsia and the increasing adoption of unhealthy lifestyles. It has been estimated that Belgium and the UK were reported to have junk food more than 5 times per month.
This report also provides the existing competitive scenario of some of the key players of the global dyspepsia drugs market which includes company profiling of AstraZeneca plc, Tkeda Phamraceuticals Company Limited, Pfizer Inc., Glaxo Smith Kline plc, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Bayer AG, Sanofi S.A, Boehringer Ingelheim International GmbH, Daiichi Snakyo Company, Limited, Otsuka Pharmaceutical Co., Ltd, Eisai Co., Ltd, Astellas Pharma Inc. and others.